^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | carboplatin (Tubulin polymerization promoter) + cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + dexamethasone (GCR agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Second-line therapy and subsequent therapy for PTCL-NOS; EATL; MEITL, AITL, including nodal PTCL, TFH, and FTCL....Combination regimens...DHA (dexamethasone and cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin)
